 "Lupin Q3 profit up 21 pct, beats estimate")
Lupin Ltd, India's third-largest drugmaker by sales, reported a 21% jump in its quarterly profit, beating analysts' estimates, helped by higher sales of its diabetes products in the United States.
Net profit for the third quarter rose to Rs 6.33 billion ($94.44 million) from Rs 5.25 billion a year ago. Analysts on average expected a profit of Rs 6.29 billion, according to Thomson Reuters.
($1 = Rs 67.0250)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories
Over 30 subscriber-only stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app